Company news

Harrow, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Harrow Announces First Quarter 2023 Financial Results

May 10, 2023

Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

May 3, 2023

Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.

May 1, 2023

Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023

April 26, 2023

Harrow Announces New $100 Million Secured Credit Facility with Oaktree

March 27, 2023

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

March 22, 2023

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%

March 12, 2023

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

March 5, 2023

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

March 1, 2023

Harrow Launches Next-Generation Compounded Atropine Formulations

February 14, 2023

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

February 1, 2023

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

January 22, 2023

Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

January 4, 2023

Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

December 20, 2022

Harrow Secures Capital to Close Recently Announced Acquisition

December 15, 2022

Harrow Prices $25 Million Offering

December 13, 2022

Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

December 13, 2022

Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

December 13, 2022

Harrow and iOR Partners Expand National Product Supply Agreement

November 29, 2022

Harrow Announces Third Quarter 2022 Financial Results

November 13, 2022

Harrow Launches Atropine.com

November 9, 2022

Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022

October 27, 2022

Harrow Sells Non-Ophthalmic Compounding Business

October 4, 2022

ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

September 28, 2022

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

September 26, 2022

Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 10, 2022

Harrow Health Announces Second Quarter 2022 Financial Results

August 8, 2022

Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022

July 26, 2022

Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States

June 23, 2022

Harrow Health Announces First Quarter 2022 Financial Results

May 4, 2022

Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference

April 21, 2022

Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022

April 19, 2022

Harrow Health Announces Appointments to Its Board of Directors

March 30, 2022

Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results

March 9, 2022

Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022

February 23, 2022

Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100

February 21, 2022

Harrow Health to Present at Aegis Virtual Conference

February 14, 2022

Harrow Health Publishes Corporate Transparency Report

February 7, 2022

Harrow Health to Participate in H.C. Wainwright BioConnect Conference

January 9, 2022

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

January 3, 2022

Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops

December 19, 2021

Harrow Health Added to the Nasdaq Biotechnology Index

December 12, 2021

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

December 6, 2021

Harrow Health Announces Third Quarter 2021 Financial Results

November 8, 2021

Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021

October 24, 2021

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

September 1, 2021

Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.

August 17, 2021

Harrow Health to Participate in Two Upcoming Virtual Investor Conferences

August 11, 2021

Harrow Health Announces Second Quarter 2021 Financial Results

August 9, 2021

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

July 26, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.